Clinical-stage drug development company Invion Limited (ASX:IVX) today announced that Dr James Campbell will be returning to a non-executive director role, effective 14 October 2013.
Having joined the Board as a non-executive director on 26 February 2012, Dr Campbell was appointed as the company’s Australian -based Executive Director following the acquisition in August 2012 of US private company Inverseon Inc.
Former Chemgenex Pharmaceuticals Limited CEO, Dr Greg Collier, was appointed Managing Director & CEO of Invion Limited in May 2013. Following a comprehensive transition period to the new Executive, Dr Campbell, who has recently been appointed CEO of New Zealand-based biotechnology company, Photonz Corporation, will now return to a non-executive role within Invion.
Invion Chairman Dr Ralph Craven thanked Dr Campbell for his contribution as an Executive Director.
“On behalf of each of the Directors of Invion, I offer our deep gratitude to James for his efforts and achievements surrounding the merger, post-merger integration and Invion’s development in these last 14 months. I look forward to James’ continuing involvement with Invion as a non-executive director,” Dr Craven said.
Dr Campbell has more than 20 years experience in scientific research, research management, management consulting and venture capital. An executive at ChemGenex Pharmaceuticals Limited for nine years prior to its sale in 2011, Dr Campbell currently sits on the Deakin University Molecular & Medical Research Advisory Board and the IP and Commercialisation Committee of the Cooperative Research Centre for Mental Health.
About Invion Limited
Invion is a clinical-stage life sciences company focussed on the development of treatments for major opportunities in the inflammatory diseases market including asthma and COPD ($34B) and systemic lupus erythematosus (lupus) (to $4B). Invion has two drug assets in three FDA-regulated, phase II clinical trials currently underway in the US. INV102 (nadolol) is a beta blocker (beta adrenergic inverse agonist) currently used in the treatment of high blood pressure and migraine that is being repurposed to treat chronic inflammatory airway diseases (e.g. asthma and COPD). The US National Institutes of Health is funding Invion’s phase II asthma program in excess of USD$4M, and a second phase II trial in chronic bronchitis (smoking cessation) is also underway. INV103 (ala-Cpn10) is a modified naturally occurring human protein shown to reduce IL-6, a key marker in the chronic inflammatory disease, lupus.